IMPROVE-AD

Currently Recruiting: Participants

Study Drug/Intervention: Thoracic endovascular aortic repair (TEVAR) versus medical therapy

Anticipated Sample Size: 1,140 patients

Study Timeline: This study is anticipated to run from July 2023 through June 2030

ClinicalTrials.gov ID:  NCT06087029

Study Objective

IMPROVE-AD aims to understand how best to treat type B aortic dissection. 

Participants must be at least 21 years old, have received a diagnosis of type B aortic dissection in the last six weeks, not have a genetic condition that can affect the aorta (such a Marfan syndrome or Vascular Ehlers-Danlos syndrome), and be receiving treatment at a participating hospital.

To learn more about IMPROVE-AD, visit the study website.